The Global Aptamers Market size is expected to reach $392.7 million by 2027, rising at a market growth of 17.6% CAGR during the forecast period.
Aptamers are oligonucleotides, such as ribonucleic acid (RNA), single-strand deoxyribonucleic acid (ssDNA), or peptide molecules, having particular three-dimensional architectures that allow them to bind to their targets with great affinity and specificity. RNA and ssDNA aptamers, in particular, might differ in sequence and folding pattern, although binding to the same target.
In the 1980s, research on the human immunodeficiency virus (HIV) and adenovirus led to the idea of combining nucleic acids with proteins. It was discovered that these viruses encode a number of short structured RNAs with excellent affinity and specificity for viral or cellular proteins. The trans-activation response (TAR) element, a short RNA ligand that binds to the viral Tat protein, stimulates trans-activation and virus replication in HIV. Virus-associated (VA)-RNA is a short RNA aptamer that modulates translation in adenoviruses.
Macugen, a vascular endothelial growth factor (VEGF)-specific aptamer approved by the Food and Drug Administration (FDA) in 2004 for the treatment of neo-vascular (wet) age-related macular degeneration (AMD), is a significant milestone in the application of aptamers.
COVID-19 is a worldwide health pandemic that causes an abnormally high rate of morbidity and mortality. SARS-CoV-2 enters host cells through clathrin-mediated endocytosis. Rapid and precise detection approaches, as well as vaccine and medication designs with SARS-CoV-2 targeting capabilities, are important in the battle against COVID-19 infections. There is an urgent need to develop safe novel biomedical technology to limit COVID-19 direct influence on public health around the world.
Moreover, breakthroughs in aptameric systems research point to the possibility of developing effective and economical diagnostics, treatments, and preventative vaccinations for SARS-CoV-2 and other infectious diseases. In addition, aptamer-based detection is the most specific, affordable, and quick detection of COVID-19 without laboratory tools.
Some of the growth catalysts for the market are improvements in aptamer development methods and rising R&D spending by leading market participants to develop and produce recombinant products. Moreover, the use of aptamers for drug discovery and illness treatment would increase in the upcoming years. In addition, ongoing research activities are displaying the effectiveness of the aptamers in different applications. Many governments are approving the use of aptamers to fulfill the demand of therapeutic and diagnostic applications.
Virus isolation in tissue cultures, immunological, and molecular approaches are all being used to diagnosis viral infections. However, these approaches have a number of problems, including the fact that they are technically demanding, expensive, and can result in false positive or false negative results, whereas an aptamer-based assay for virus detection may alleviate some of these issues.
Aptamers have a low affinity, which is one of their key disadvantages. Despite the fact that aptamers can target a wide range of compounds, research have revealed that they do not have strong affinities for all of them. Certain interactions between the aptamer and the target molecule can be limited by the oligonucleotide structure of aptamers. Aptamers' targets are mostly found in blood plasma or cells that can be accessed by blood plasma.
Based on the Type, the aptamers market is categorized in DNA Aptamers, XNA Aptamers, and RNA Aptamers. In 2020, the DNA-based aptamers segment dominated the aptamers market with the highest revenue share of the market. The substantial growth of this segment is attributed to their lower production costs and improved stability when compared to other nucleic acid-based aptamers, as well as their widespread availability.
Based on the Application, the Aptamers market is segregated into Therapeutics Development, Research & Development, Diagnostics, and Others. In 2020, the diagnostic segment held a promising revenue share of the Aptamers Market. The significant growth rate of the segment is attributed to the rapidly increasing frequency of chronic diseases and disorders as well as the development of novel diagnostic kits to identify cancer and other diseases and disorders. Moreover, the most important component in the treatment of diseases, particularly viral disorders, is an accurate diagnosis.
Based on the Technology, the Aptamers market is bifurcated into SELEX and Others. In 2020, the SELEX technology segment obtained the largest revenue share of the aptamers market. The significant revenue share of the segment can be attributed to the fact that SELEX is one of the most commonly utilized technologies to perform the process of isolating high-affinity single-stranded DNA and RNA from a broad line of random sequences. This is due to the constantly increasing focus on innovating technologies for aptamer selection.
Based on the End-user, the Aptamers market is divided into Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs, and Others. In 2020, Pharmaceutical & Biotechnology Companies segment acquired the largest revenue share of the aptamers market. This is owing to the growing number of market players offering aptamers for usage in therapeutics development and rising R&D spending.
| Report Attribute | Details |
|---|---|
| Market size value in 2020 | USD 137.6 Million |
| Market size forecast in 2027 | USD 392.7 Million |
| Base Year | 2020 |
| Historical Period | 2017 to 2019 |
| Forecast Period | 2021 to 2027 |
| Revenue Growth Rate | CAGR of 17.6% from 2021 to 2027 |
| Number of Pages | 233 |
| Number of Tables | 450 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling |
| Segments covered | Type, Application, Technology, End User, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Based on the Region, the Aptamers market is analyzed across North America, Europe, APAC, and LAMEA. In 2020, North America emerged as the leading region in the overall Aptamers market by collecting the maximum revenue share of the market. This is attributed to the availability of funds to develop innovative technologies, the presence of prominent market players, and growing collaborations among companies. Moreover, some of the key trends of the regional market are rapid rate of technological breakthroughs and substantial investment and funding to assist the development of aptamers.
Free Valuable Insights: Global Aptamers Market size to reach USD 392.7 Million by 2027
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Kaneka Corporation, Aptamer Group PLC, SomaLogic, Inc., RayBiotech Life, Inc., Neoventures Biotechnology, Inc., Maravai Lifesciences Holdings, Inc., Aptus Biotech, Base Pair Biotechnologies, Inc., Alpha Diagnostic International, Inc., and Vivonics, Inc.
By Type
By Application
By Technology
By End User
By Geography
The global aptamers market size is expected to reach $392.7 million by 2027.
Growing applications of aptamer in Virus Detection of the companies are driving the market in coming years, however, lesser acceptance in market in comparison to antibodies have limited the growth of the market.
Kaneka Corporation, Aptamer Group PLC, SomaLogic, Inc., RayBiotech Life, Inc., Neoventures Biotechnology, Inc., Maravai Lifesciences Holdings, Inc., Aptus Biotech, Base Pair Biotechnologies, Inc., Alpha Diagnostic International, Inc., and Vivonics, Inc.
SELEX acquired maximum revenue share in the Global Aptamers Market by Technology 2020, and would continue to be a dominant market till 2027.
RNA Aptamers segment has high growth rate of 19.9% during (2021 - 2027). The growth of this segment is due to its high therapeutic as well as diagnostic value.
The North America market is the fastest growing region in the Global Aptamers Market by Region 2020, and would continue to be a dominant market till 2027.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 